Prognostic Nomograms for Primary High-Grade Glioma Patients in Adult: A Retrospective Study Based on the SEER Database.
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
04
2020
revised:
13
06
2020
accepted:
23
06
2020
entrez:
11
8
2020
pubmed:
11
8
2020
medline:
23
4
2021
Statut:
epublish
Résumé
In our study, we aimed to screen the risk factors that affect overall survival (OS) and cancer-specific survival (CSS) in adult glioma patients and to develop and evaluate nomograms. Primary high-grade gliomas patients being retrieved from the surveillance, epidemiology and end results (SEER) database, between 2004 and 2015, then they randomly assigned to a training group and a validation group. Univariate and multivariate Cox analysis models were used to choose the variables significantly correlated with the prognosis of high-grade glioma patients. And these variables were used to construct the nomograms. Next, concordance index (C-index), calibration plot and receiver operating characteristics (ROCs) curve were used to evaluate the accuracy of the nomogram model. In addition, the decision curve analysis (DCA) was used to analyze the benefit of nomogram and prognostic indicators commonly used in clinical practice. A total of 6395 confirmed glioma patients were selected from the SEER database, divided into training set (n =3166) and validation set (n =3229). Age at diagnosis, tumor grade, tumor size, histological type, surgical type, radiotherapy and chemotherapy were screened out by Cox analysis model. For OS nomogram, the C-index of the training set was 0.741 (95% CI: 0.751-0.731), and the validation set was 0.738 (95% CI: 0.748-0.728). For CSS nomogram, the C-index of the training set was 0.739 (95% CI: 0.749-0.729), and the validation set was 0.738 (95% CI: 0.748-0.728). The net benefit and net reduction in inverventions of nomograms in the decision curve analysis (DCA) was higher than histological type. We developed nomograms to predict 3- and 5-year OS rates and 3- and 5-year CSS rates in adult high-grade glioma patients. Both the training set and the validation set showed good calibration and validation, indicating the clinical applicability of the nomogram and good predictive results.
Identifiants
pubmed: 32775408
doi: 10.1155/2020/1346340
pmc: PMC7397389
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1346340Informations de copyright
Copyright © 2020 Yi Yang et al.
Déclaration de conflit d'intérêts
The authors declare there are no competing interests.
Références
Neurosurgery. 2013 Feb;72(2):N19
pubmed: 23328659
Oncol Lett. 2019 Aug;18(2):1863-1871
pubmed: 31423255
J Clin Oncol. 2013 Jan 20;31(3):337-43
pubmed: 23071247
Aging health. 2011 Oct 1;7(5):707-718
pubmed: 22121388
Neuro Oncol. 2018 Feb 19;20(3):324-331
pubmed: 29016869
J Cancer. 2019 Jun 2;10(14):3232-3238
pubmed: 31289594
Cancer Manag Res. 2020 Feb 03;12:769-775
pubmed: 32099472
Brain. 2014 Feb;137(Pt 2):449-62
pubmed: 24374407
Semin Radiat Oncol. 2010 Jan;20(1):3-11
pubmed: 19959026
J Neurosurg. 2011 Aug;115(2):240-4
pubmed: 21529134
Lancet Oncol. 2014 Aug;15(9):e395-403
pubmed: 25079102
Clin Neurol Neurosurg. 2012 Oct;114(8):1135-44
pubmed: 22425370
Oncol Lett. 2017 Nov;14(5):5418-5426
pubmed: 29113174
J Neurooncol. 2017 Mar;132(1):119-126
pubmed: 28025770
Neurosurg Focus. 2013 Feb;34(2):E5
pubmed: 23373450
J Neurosurg. 2008 Feb;108(2):227-35
pubmed: 18240916
Medicine (Baltimore). 2018 Dec;97(52):e13900
pubmed: 30593203
Mol Neurobiol. 2018 Jan;55(1):402-408
pubmed: 27975172
Lancet. 2012 May 26;379(9830):1984-96
pubmed: 22510398
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Neurosurg Rev. 2018 Apr;41(2):599-604
pubmed: 28856492
Semin Oncol Nurs. 2018 Dec;34(5):420-429
pubmed: 30392758
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
J Neurooncol. 2016 Nov;130(2):269-282
pubmed: 27174197
Int J Surg. 2016 Sep;33 Pt A:60-4
pubmed: 27475744
J Neurosurg. 2001 Aug;95(2):190-8
pubmed: 11780887
J Clin Oncol. 2008 Mar 10;26(8):1338-45
pubmed: 18323558
J Neurooncol. 2019 Dec;145(3):479-486
pubmed: 31621041
J Neurosurg. 2012 Dec;117(6):1039-52
pubmed: 23039150
Neuro Oncol. 2015 Apr;17(4):505-15
pubmed: 25204555
JAMA. 2013 Nov 6;310(17):1842-50
pubmed: 24193082
Neurosurgery. 2011 May;68(5):1326-33
pubmed: 21307795
BMC Cancer. 2020 Jan 31;20(1):79
pubmed: 32005184
Crit Rev Oncol Hematol. 2010 Apr;74(1):40-60
pubmed: 19577481
J Clin Oncol. 2012 Jun 1;30(16):2005-12
pubmed: 22547602
Neuro Oncol. 2015 Jun;17(6):868-81
pubmed: 25556920
Cancer Treat Res. 2015;163:1-14
pubmed: 25468222
Clin Neuropathol. 2017 Nov/Dec;36(6):263-271
pubmed: 28933335
N Engl J Med. 2009 Feb 19;360(8):765-73
pubmed: 19228619
Oncology. 2000 Feb;58(2):108-16
pubmed: 10705237
BMC Cancer. 2011 Jul 29;11:325
pubmed: 21801393
Neuro Oncol. 2015 Apr;17(4):623-4
pubmed: 25605816
Neuro Oncol. 2019 Feb 14;21(2):179-188
pubmed: 30321384
World Neurosurg. 2020 Jan;133:237-239
pubmed: 31627003
Indian J Cancer. 2016 Jul-Sep;53(3):382-386
pubmed: 28244465
Neurosurg Rev. 2019 Jun;42(2):263-275
pubmed: 29138949
World Neurosurg. 2017 Jul;103:180-185
pubmed: 28377251
Cancer. 2003 Dec 1;98(11):2430-9
pubmed: 14635078
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Neurocirugia (Astur). 2017 Nov - Dec;28(6):276-283
pubmed: 28965807
J Clin Oncol. 2013 Jan 20;31(3):344-50
pubmed: 23071237
JAMA Oncol. 2016 Nov 1;2(11):1460-1469
pubmed: 27310651